{"filing":{"accession_number":"0001104659-26-076819","cik":"0002020932","ticker":"AGMB","company_name":"Agomab Therapeutics NV","form":"6-K","filing_date":"2026-06-23","report_date":null,"primary_document":"tm2618511d1_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2020932/000110465926076819/tm2618511d1_6k.htm"},"events":[{"id":13164,"run_id":11684,"accession_number":"0001104659-26-076819","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces the design and regulatory alignment of a Phase 2b clinical trial (NOV-ERA study) for ontunisertib in fibrostenosing Crohn's disease, including FDA alignment on primary endpoints, protocol submission to regulatory agencies, and expected study initiation in H2 2026. This is a material operational/clinical development milestone for a clinical-stage biopharmaceutical company, representing significant progress in late-stage development of a key product candidate, but does not fit the discrete event categories (earnings, M\u0026A, executive changes, etc.) and is best classified as an operational milestone.","company_name":"Agomab Therapeutics NV","ticker":"AGMB","filing_date":"2026-06-23","form":"6-K","submitted_at":null,"items":[{"id":10231,"accession_number":"0001104659-26-076819","item_number":"EX-99.1","item_title":"tm2618511d1_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces the design and regulatory alignment of a Phase 2b clinical trial (NOV-ERA study) for ontunisertib in fibrostenosing Crohn's disease, including FDA alignment on primary endpoints, protocol submission to regulatory agencies, and expected study initiation in H2 2026. This is a material operational/clinical development milestone for a clinical-stage biopharmaceutical company, representing significant progress in late-stage development of a key product candidate, but does not fit the discrete event categories (earnings, M\u0026A, executive changes, etc.) and is best classified as an operational milestone.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-23T20:14:38.051963+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10231,"accession_number":"0001104659-26-076819","item_number":"EX-99.1","item_title":"tm2618511d1_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces the design and regulatory alignment of a Phase 2b clinical trial (NOV-ERA study) for ontunisertib in fibrostenosing Crohn's disease, including FDA alignment on primary endpoints, protocol submission to regulatory agencies, and expected study initiation in H2 2026. This is a material operational/clinical development milestone for a clinical-stage biopharmaceutical company, representing significant progress in late-stage development of a key product candidate, but does not fit the discrete event categories (earnings, M\u0026A, executive changes, etc.) and is best classified as an operational milestone.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-23T20:14:38.051963+00:00","company_name":"Agomab Therapeutics NV","ticker":"AGMB","filing_date":"2026-06-23"}]}